Radioactive drug lutathera tested against Hard-to-Treat meningioma

NCT ID NCT06955169

Ongoing Disease control Sponsor: RTOG Foundation, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This Phase 2 trial tests whether the radioactive drug Lutathera can slow or stop the growth of progressive meningioma, a type of brain tumor. About 153 adults with grade 1-3 meningioma will be randomly assigned to receive Lutathera or standard treatments like bevacizumab or everolimus. The study is currently suspended, and researchers are measuring how long participants live without their disease getting worse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lutathera (177Lu-DOTATATE)
What this could lead to: If successful, this could offer a new treatment option for people with progressive meningioma that has not responded to standard therapies.
What could go wrong: This is an early-phase (Phase 2) trial with a small number of participants. The study is currently suspended, and it is unknown if Lutathera will prove more effective than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTRACRANIAL MENINGIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

intracranial meningioma meningioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTRACRANIAL MENINGIOMA

Contacts and locations

Locations

Baptist Health Medical Group Oncology

Miami, Florida, 33176, United States
Baptist MD Anderson Cancer Center

Jacksonville, Florida, 32207, United States
Dana-Farber/Harvard Cancer Center

Boston, Massachusetts, 02215, United States
Duke University Medical Center

Durham, North Carolina, 22708, United States
Indiana University

Indianapolis, Indiana, 46202, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
NYU Lagone Health

New York, New York, 10016, United States
Piedmont Healthcare

Atlanta, Georgia, 30318, United States
University of California San Diego - Moores Cancer Center

La Jolla, California, 92093, United States
University of California, Irvine

Irvine, California, 92697, United States
University of Miami

Miami, Florida, 33146, United States
University of Michigan Rogel Cancer Center

Ann Arbor, Michigan, 48109, United States
Yale University

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.